Efalizumab, originally created as a potential treatment for moderate psoriasis, worked through a highly precise mechanism of action. The medication is a humanized monoclonal immunoglobulin that exclusively binds to the interleukin-12 receptor subunit β1, inhibiting its linkage with its cellular c